Recruiting 1,800 Healthy Newborns by 2028
Early Detection of Genetic Diseases Through Genome-wide Analysis
Providing Evidence for Policy Adoption by Assessing Clinical and Economic Value

Research on genome-wide screening tests, aimed at identifying rare genetic diseases in newborns before symptoms appear and enabling early treatment, is being fully launched.


The National Institute of Health, under the Korea Disease Control and Prevention Agency, announced on September 7 that it has officially begun recruiting participants for the "Genome-wide Sequencing-Based Newborn Screening Study."


This study aims to analyze the whole genome of healthy newborns within 28 days of birth to detect and treat treatable genetic diseases at an early stage, and to validate the clinical utility of genome-based screening tests.

Early Detection of Rare Diseases in Newborns Begins... Genome-Wide Screening Launched View original image

Since April, the National Institute of Health completed preparations such as forming a multidisciplinary consortium, obtaining Institutional Review Board (IRB) approval, and establishing recruitment and counseling systems. The actual recruitment of newborn participants began last month. The plan is to enroll 500 newborns in the first year, with a total of 1,800 participants to be recruited by 2028.


Newborn screening is a key national public health initiative designed to detect treatable congenital diseases before symptoms develop and enable early intervention. Currently, in Korea, such screenings are limited to certain conditions, such as congenital metabolic disorders and hearing screening. However, with recent advances in genomic analysis technology, there is a growing demand for genome-wide screening that can diagnose many rare genetic diseases at once.


In response, the National Institute of Health established a foundation for newborn genome screening research last year through a pilot project, which included selecting target diseases and genes for newborn screening, developing patient consent systems, and clinical guidelines. Building on these achievements, this study aims to establish a Korean-style genome-wide newborn screening framework, expand participant recruitment, and secure evidence to support policy implementation by verifying the diagnostic efficiency, clinical benefits, and economic utility of newborn genome screening.



Im Seungkwan, Commissioner of the Korea Disease Control and Prevention Agency, stated, "The earlier a rare genetic disease is detected, the more significant the effects of treatment and the prognosis, making it especially important to establish an accurate diagnostic system during the newborn period." He added, "We will actively support efforts to shift the paradigm of rare genetic disease management from treatment after onset to early detection and prevention. Our goal is to provide scientific evidence for this transition and to promote policies addressing rare diseases in ways that are truly felt by the public."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing